Abstract:

Objective

To investigate the relationship between the expressions of estrogen receptor(ER),human epidermal growth factor receptor-2(HER-2),P53 and Ki67 and the therapeutic effect of neoadjuvant chemotherapy for breast cancer.

Methods

One hundred and sixty-five patients treated with 4～6 cycles of neoadjuvant taxanes and anthracyclines chemotherapy in our centre between Oct 2007 and Sep 2009 were included in this retrospective study.The expressions of ER,HER-2,P53 and Ki67 were detected by immunohistochemistry method before neoadjuvant chemotherapy.We used pathology to evaluate the therapeutic effectiveness and considered G4 and G5 as efficiency.Fourfold table Chi squaretest was used to analyze the relationship between the features above and the therapeutic effectiveness.

Results

The overall efficiency rate of neoadjuvant chemotherapy among the 165 patients was 56.4% (93/165).The efficiency rate was 43.5%(20/46)for ER positive patients,and 61.3%(73/119)for ER negative patients;the difference between the two groups was significant(χ²=4.31;P=0.04).HER-2 over-expressed patients achieved efficiency rate of 72.0%(36/50),and HER-2 lowly expressed patients 49.6% (57/115),with significant difference between the two groups(χ²=7.13,P=0.01).The efficiency rate was 66.7%(30/45)for P53 positive patients,and 53.4%(47/88)for negative patients,with no significant difference between the two groups(χ²=2.15,P=0.14).Ki67 over-expressed patients acquired 62.4% (68/109)efficiency rate,and the lowlyexpressed ones 44.0%(22/50),with statistical difference(χ²=4.72,P=0.03).

Conclusions

The results manifest that ER negative,HER-2 over-expressed and Ki67 over-expressed patients are more susceptive to neoadjuvant taxanes plus anthracyclines chemotherapy.The expression status of ER,HER-2 and Ki67 can well predict the efficiency of neoadjuvant chemotherapy.

Key words: Estrogen receptor, Human epidermal growth factor receptor-2, P53, Ki67, Neoadjuvant chemotherapy, Breast neoplasms